NEW YORK–(BUSINESS WIRE) March 03, 2021 — The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for Lorbrena® (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase…
Read More3D metal printer expands possibilities for innovation
When the Zucker Institute for Applied Neurosciences at the Medical University of South Carolina needed to bring to life a neurosurgeon’s idea for better instrumentation for sacroiliac surgery, there was one obvious partner to turn to: the MUSC College of…
Read More